^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anti-BCMA CAR-T cells

    i
    Associations

    News

    Trials
    Company:
    Hrain Biotech
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Hrain Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    anti-BCMA CAR-T cells
    over2years
    Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM (clinicaltrials.gov)
    P2, N=100, Recruiting, Hrain Biotechnology Co., Ltd.
    New P2 trial
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CRP (C-reactive protein)
    |
    anti-BCMA CAR-T cells